NCT07712692尚未招募2 期
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of NWRD09 in Patients With HPV16-Positive Cervical High-Grade Squamous Intraepithelial Lesion (HSIL)
Newish Biotech (Wuxi) Co., Ltd.15 个研究点 分布在 1 个国家目标入组 156 人开始时间: 2026年8月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 156
- 试验地点
- 15
- 主要终点
- Proportion of Participants with Histopathological Regression of Cervical Lesions to non-HSIL (LSIL/CIN1 or no lesion) at week 24.
研究概览
简要总结
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD09 administered by intramuscular (IM) injection in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) associated with human papillomavirus (HPV) 16.
详细描述
This is a Phase II, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of NWRD09 in patients with HPV16 positive cervical high-grade squamous intraepithelial lesion (HSIL). Eligible participants are randomized to receive either NWRD09 or the corresponding placebo.
Participants will receive intramuscular injections of either NWRD09 or matching placebo at the corresponding dose at weeks 0, 2, 4, and 12 (a total of 4 doses).
Efficacy evaluations at Week 24 will include histopathological biopsy and HPV testing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participants had to meet all of the following inclusion criteria:
- •Age between 18 and 65 years (inclusive), female;
- •Confirmed by the central laboratory: histopathologically diagnosed cervical high-grade squamous intraepithelial lesion (HSIL) and HPV genotyping positive for HPV16;
- •Colposcopy results at each study center during the screening period must meet the following criteria:
- •1) The colposcopy examination is adequate, allowing clear visualization of the entire area of acetowhite epithelium or suspected cervical intraepithelial neoplasia (CIN) lesions, including the upper margin of the lesion; 2) If the upper margin of the lesion is not clearly visible, the endocervical curettage (ECC) result must be negative; 3) The area of cervical lesion is less than 75% of the cervical area visible by colposcopy; (4) Within 14 days (inclusive) before the first dose, major organ function meets the following criteria:
- •Hematology: hemoglobin (Hb) ≥ 100 g/L; platelet count (PLT) ≥ 75 × 10⁹/L; absoluteneutrophil count ≥ 1.8 × 10⁹/L;
- •Liver: total bilirubin (TB) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; plasma albumin ≥ 30 g/L;
- •Kidney: serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (Ccr) ≥ 40 mL/min (calculated by Cockcroft-Gault formula); (5) For premenopausal women with childbearing potential, serum pregnancy test within 14 days before the first dose must be negative. Eligible participants of childbearing potential and their spouse/partner must agree to use effective contraceptive measures during the study period or until 64 weeks after the first dose; (6) Fully understand the study and voluntarily sign the informed consent form (ICF), be able to communicate well with the investigator, and be able to complete all treatments, examinations, and visits as required by the study protocol.
排除标准
- •Participants with any of the following were excluded from the study:
- •Any histopathologically confirmed cervical adenocarcinoma/adenocarcinoma in situ (AIS), vulvar, vaginal, or anal high-grade intraepithelial lesions, or invasive cancer;
- •Women who are pregnant or breastfeeding, or who plan to become pregnant during the study period;
- •Participation in another clinical trial within 30 days prior to screening, or currently being in the follow-up period of another clinical trial;
- •Continuous use (for more than 1 week) of systemic glucocorticoid therapy (at a dose equivalent to >10 mg/day prednisone or equivalent dose of other glucocorticoids) or other immunosuppressive agents within 30 days prior to screening, except for the following:
- •Inhaled, ophthalmic, or topical glucocorticoid therapy at a dose ≤10 mg/day prednisone or equivalent is permitted;
- •Physiological glucocorticoid replacement therapy at a dose ≤10 mg/day prednisone or equivalent;
- •Continuous use (for more than 1 week) of immunosuppressants such as cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, anti-lymphocyte globulin, etc., within 30 days prior to screening;
- •Receipt of any live vaccine within 4 weeks prior to the first dose, and/or any non-live vaccine within 2 weeks prior to the first dose;
- •Any history of therapeutic HPV vaccination (approved prophylactic HPV vaccination is acceptable);
- •Receipt of any drug or physical therapy for HSIL within 4 weeks prior to screening;
- •Use of blood or blood-related products (including immunoglobulin) within 3 months prior to the first dose, or planned use during the study period;
- •History of immunodeficiency or autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, etc.), or currently active autoimmune disease requiring systemic treatment (e.g., with disease-modifying agents, corticosteroids, or immunosuppressants);
- •Current or anticipated continuous use (for more than 1 week) of disease-modifying antirheumatic drugs (e.g., azathioprine, cyclophosphamide, cyclosporine, methotrexate) and biologic disease-modifying antirheumatic drugs (e.g., infliximab, adalimumab, etanercept) during the study period;
- •History of solid organ or bone marrow transplantation;
- •Previous or current other malignancy;
- •Uncontrolled serious infection (> Grade 2 NCI-CTCAE, version 6.0);
- •Positive test for hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum antibody; positive for hepatitis B surface antigen (HBsAg) unless HBV-DNA ≤ 2500 copies/mL or ≤ 500 IU/mL or within the normal range of the study site;
- •Known allergy to any component of the investigational drug or similar drugs; history of severe allergic reactions to food, drugs, or other substances (e.g., urticaria, eczema, dyspnea, angioedema, etc.);
- •Tattoos, scars, or active lesions/rash within 2 cm of the intended injection site (deltoid of the upper arm) that may affect safety observation;
- •Severe dysfunction of other organs or cardiopulmonary disease;
- •Definite history of neurological or psychiatric disorders, including epilepsy or dementia;
- •History of drug abuse or alcohol use disorder;
- •History or current evidence of any condition, treatment, laboratory abnormality, or other circumstances that may increase the risk of study participation or investigational product administration, or may interfere with interpretation of study results, and in the judgment of the investigator, make the participant unsuitable for enrollment in this study.
结局指标
主要结局
Proportion of Participants with Histopathological Regression of Cervical Lesions to non-HSIL (LSIL/CIN1 or no lesion) at week 24.
时间窗: Week24
The number of participants with histopathologically confirmed CIN2/3 whose cervical lesions regress to CIN 1 or no lesions at the 24 week visit.
次要结局
- Incidence and severity of local and systemic adverse events (AEs).(Up to week 64)
- Incidence and severity of all serious adverse events (SAEs).(Up to week 64)
- Pregnancy occurrences and outcomes during the study period.(Up to week 64)
- Incidence of investigational product-related adverse events (AEs) leading to treatment discontinuation.(Up to week 64)
- Proportion of Participants with Histopathological Regression of Cervical Lesions to no lesions.(Week 24)
- Proportion of Participants with Histopathological regression of Cervical Lesions to LSIL/CIN1.(Week 24)
- Proportion of Participants with Virologically-proven Clearance of HPV 16.(Week 24)
- Proportion of Participants with Histopathological Regression of Cervical Lesions to non-HSIL(LSIL /CIN1 or lesion) and with Virologically-proven Clearance of HPV 16.(Week 24)
- Proportion of Participants with Histopathological Regression of Cervical Lesions to no Lesion and with Virologically-proven Clearance of HPV 16.(Week 24)
- Proportion of Participants with Histopathological Regression to non-HSIL (LSIL/CIN1 or no lesion) in Participants with Baseline HPV16-only Infection.(Week 24)
- Proportion of Participants with Histopathological Regression to no Lesion in Participants with Baseline HPV16-only Infection.(Week 24)
- Proportion of Participants with Virologically-proven Clearance of Both HPV16 and non-HPV16 in Participants with Baseline Co-infection with non-HPV16.(Week 24)
- Proportion of Participants with Virologically-proven Clearance of non-HPV16 in Participants with Baseline Co-infection with non-HPV16.(Week 24)
- Levels of cellular immune responses.(Weeks 4, 8, 16, 24 and 48)
- Levels of serum anti-HPV16 antibody titers.(Weeks 4, 8, 16, 24 and 48)
研究者
研究点 (15)
Loading locations...
相似试验
尚未招募
2/3 期
Sildenafil Oral Spray for Radiation-Induced Oral MucositisCTRI/2026/01/101504ICMR80
招募中
2 期
A Phase II Study of 9MW3811 in Patients With Pathological ScarScarNCT07576608Mabwell (Shanghai) Bioscience Co., Ltd.30
招募中
2 期
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes MellitusNCT07282743Sun Pharmaceutical Industries Limited285
进行中（未招募）
2 期
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678Ascletis Pharma (China) Co., Limited100
进行中（未招募）
2 期
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsType 2 DiabetesNCT07502495Biomea Fusion Inc.64